My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Sapanisertib (NK128; MLN0128; TAK228)
    Sapanisertib (NK128; MLN0128; TAK228)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0185
    CAS #: 1224844-38-5Purity ≥98%

    Description: Sapanisertib (NK-128; MLN-0128; TAK-228) is a novel, potent, orally bioavailable and selective inhibitor of mTOR (mammalian target of rapamycin) with potential anticancer activity. It inhibits mTOR with an IC50 of 1 nM in cell-free assays. In a ZR-75-1 breast cancer xenograft model, INK 128 shows tumor growth inhibition efficacy at a dose of 0.3 mg/kg/day. Daily, oral administration of INK 128 inhibits angiogenesis and tumor growth in multiplexenograft models.

    References: Nature. 2012 Feb 22;485(7396):55-61; Drug Discov Today Ther Strateg. 2009; 6(2):47-55.

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review

    Molecular Weight (MW)

    309.33

    Formula

    C15H15N7O

    CAS No.

    1224844-38-5

    Storage

    -20℃ for 3 years in powder form

    -80℃ for 2 years in solvent

    Solubility (In vitro)

    DMSO: 62 mg/mL (200.4 mM)

    Water: <1 mg/mL

    Ethanol: 2 mg/mL (6.5 mM)

    Solubility (In vivo)

    30% PEG400+0.5% Tween80+5% propylene glycol: 30mg/mL

    Synonyms

    MLN-0128; Sapanisertib; TAK-228; TAK 228; TAK228; INK128; INK-128; INK 128; MLN0128; MLN 0128; MLN-0128 

    Chemical Name: 3-(2-amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

    InChi Key: GYLDXIAOMVERTK-UHFFFAOYSA-N

    InChi Code: InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)

    SMILES Code: NC1=C2C(N(C(C)C)N=C2C3=CC=C(OC(N)=N4)C4=C3)=NC=N1



    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2

    In Vitro

    Kinase Assay: Sapanisertib (INK-128) is a ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase. Sapanisertib (INK-128) exhibits an enzymatic inhibition activity against mTOR and more than 100-fold selectivity to PI3K kinases.

     

    Cell Assay: INK 128 exhibits an enzymatic inhibition activity against mTOR and more than 100-fold selectivity to PI3K kinases. As TORC1/2 inhibitor, INK 128 inhibits both the phosphorylation of S6 and 4EBP1, the downstream substrates of TORC1, and selectively inhibits AKT phosphorylation at Ser473, the downstream substrate of TORC2. Furthermore, INK 128 also shows potent inhibition effects on cell lines resistant to rapamycin and pan-PI3K inhibitors.

    In Vivo

    In a ZR-75-1 breast cancer xenograft model, INK 128 shows tumor growth inhibition efficacy at a dose of 0.3 mg/kg/day. Daily, oral administration of INK 128 inhibits angiogenesis and tumor growth in multiplexenograft models.

    Animal model

    Nude Mice

    Formulation & Dosage

    Nude mice are inoculated subcutaneously in the right subscapular region with 5×106 MDA-MB-361 cells. After tumours reach a size of 150-200 mm3, mice are randomLy assigned into vehicle control or treatment groups. Sapanisertib (INK-128) is formulated in 5% polyvinylpropyline, 15% NMP, 80% water and administered by oral gavage at 0.3 mg/kg and 1 mg/kg daily.

    References


    Nature. 2012 Feb 22;485(7396):55-61; Drug Discov Today Ther Strateg. 2009; 6(2):47-55.



    These protocols are for reference only. InvivoChem does not independently validate these methods.

    INK 128 (MLN0128)

    Ribosome profiling reveals mTOR-dependent specialized translational control of the prostate cancer genome.  2012 Feb 22;485(7396):55-61.

    INK 128 (MLN0128)

    mTOR promotes prostate cancer cell migration and invasion through a translationally regulated gene signature.

    INK 128 (MLN0128)

    TheThe 4EBP1–eIF4E axis controls the post-transcriptional expression of mTOR-sensitive invasion genes.  2012 Feb 22;485(7396):55-61

    INK 128 (MLN0128)

    mTOR hyperactivation augments translation of YB1, MTA1, CD44 and vimentin mRNAs in a subset of pre-invasive prostate cancer cells in vivo.  2012 Feb 22;485(7396):55-61. 

    INK 128 (MLN0128)

    Complete mTOR inhibition by INK128 treatment prevents prostate cancer invasion and metastasis in vivo.  2012 Feb 22;485(7396):55-61. 

    INK 128 (MLN0128)

    INK 128 (MLN0128)


    INK 128 (MLN0128)

    mTOR signal pathway.  2009 Summer;6(2):47-55.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?